Pipeline Regulatory Progress -- Two risk-adjusted product launches (AMP-002 and AMP-015) are included in the flat full-year ...

The approval of epinephrine pre-filled syringes marks the final approval for these products as ANDAs or NDAs, so we have achieved our commitment to the FDA that we would get approvals for all of ...

The syringes are said to be produced using a hands-free and fully automated process to minimise contamination risks.

The global market for Prefilled Syringes was estimated at US$7.5 Billion in 2023 and is projected to reach US$13.3 Billion by 2030, growing at a CAGR of 8.6% from 2023 to 2030.

Symjepi Jr., the low-dose version of Adamis’ Symjepi epinephrine prefilled syringe, faces a PDUFA decision expected Thursday, Sep. 27; approval is broadly anticipated, given the adult variant ...

Amphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved the Company's New Drug Application for Epinephrine injection USP, 1 mg/10mL Single Dose Pre-Filled ...